跳至主要内容
临床试验/NCT05822089
NCT05822089
招募中
不适用

Comparison of Visual Outcomes of Enhanced Monofocal Intraocular Lenses

Medical University of Vienna1 个研究点 分布在 1 个国家目标入组 461 人2021年12月13日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Age Related Cataracts
发起方
Medical University of Vienna
入组人数
461
试验地点
1
主要终点
Contrast sensitivity and reading ability - Vivinex XC1 and Vivinex XY1
状态
招募中
最后更新
4个月前

概览

简要总结

The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved investigational plan.

注册库
clinicaltrials.gov
开始日期
2021年12月13日
结束日期
2026年12月31日
最后更新
4个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Christina Leydolt

Assoc. Prof. PD Dr

Medical University of Vienna

入排标准

入选标准

  • Bilateral age-related cataract planned for phacoemulsification extraction and posterior IOL implantation
  • Age 50 to 100
  • Visual potential in both eyes of 20/25 or better as determined by investigators estimation
  • Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
  • Irregular Astigmatism (Acrysof IQ Vivity IOL, IC-8 Apthera IOL)
  • postoperativ binocular best corrected distance visual acuity (BCVA) ≥ 1.0 decimal (Arm ten (X))
  • Standard cataract surgery with bilateral implantation of a monofocal IOL (Vivinex XC1 or Vivinex XY1) (Arm ten (X))

排除标准

  • Preceding intraocular surgery or ocular trauma
  • Relevant other ophthalmic diseases that particularly effects the zonular apparatus (such as severe pseudoexfoliation syndrome, preceding cryocoagulation, trauma)
  • Pupil diameter \< 2.0 mm (photopic)
  • Laser treatment
  • Uncontrolled systemic or ocular disease
  • Pregnancy/Nursing
  • childbearing ability

结局指标

主要结局

Contrast sensitivity and reading ability - Vivinex XC1 and Vivinex XY1

时间窗: 2-6 months and 1-5 years

Primary outcome measures for arm ten (X) will be the distance corrected contrast sensitivity and near corrected reading ability and reading speed. Contrast sensitivity will be assessed under standard photopic (85cd/m2) and mesopic (3cd/m2) conditions

Distant corrected intermediate visual acuity

时间窗: 2-6 months

Primary outcome measure will be monocular distant corrected intermediate visual acuity (DCIVA) of each intraocular lens implanted. DCIVA will be assessed using standardized early treatment diabetic retinopathy study (EDTRS) charts on a logarithm of the minimum angle of resolution (logMAR) scale.

Best-corrected distance visual acuity (BCDVA) - Acrysof IQ Vivity IOL, IC-8 Apthera IOL

时间窗: 3-5 months

Primary outcome measure will be monocular best-corrected distance visual acuity (BCDVA) of each intraocular lens implanted in eyes with irregular astigmatism. BCDVA will be assessed using standardized early treatment diabetic retinopathy study (EDTRS) charts on a logarithm of the minimum angle of resolution (logMAR) scale.

次要结局

  • Contrast sensitivity and reading ability(2-6 months and 1-5 years)

研究点 (1)

Loading locations...

相似试验